Cymbeline Culiat, Ph. D.

President and Chief Scientific Officer

Cymbeline (Bem) Culiat studied the genetic and molecular basis of early mammalian development for nearly a decade as a senior scientist at Oak Ridge National Laboratory (ORNL), Oak Ridge, TN. Her studies led to the discovery of the role of the NELL1 protein in pathways controlling growth and maturation of the musculoskeletal and cardiovascular systems. This discovery is the foundation on which NellOne Therapeutics (NellOne), was established in 2008. Dr. Culiat is the inventor on issued and pending patents related to the veterinary and human clinical applications of NELL1 in skeletal muscle wound healing and treatment of cardiovascular disorders, which are exclusively licensed worldwide to NellOne.

While on staff at ORNL Dr. Culiat’s entrepreneurial interests grew with her deep involvement in technology innovation and commercialization through her six-year participation in the seed grant, invention disclosure and technology maturation programs. She took an early retirement from ORNL to join NellOne in 2011 as Chief Scientific Officer and expanded this role when she became President of the company in 2012.

Born, raised and educated in the Philippines, Dr. Culiat taught biology (1981-1994) at the University of the Philippines in Laguna, where she earned a B.S. degree in Cell Biology (cum laude) and an M.S. degree in Genetics. In 1994, Dr. Culiat received her doctorate in Biomedical Sciences from ORNL-University of Tennessee (Knoxville, TN) as a scholar of ORNL and the Hilton-Smith Fellowship. She was awarded the Chancellor’s citation for Professional Promise. Dr. Culiat completed postdoctoral work in Molecular Genetics and Genomics at ORNL, as an awardee of the U.S. Department of Energy’s (DOE) prestigious Alexander Hollaender Distinguished Postdoctoral Fellowship (1996-1999). While on the ORNL R&D staff (1999-2009), she was also an adjunct faculty member of the College of Arts and Sciences, Graduate School of Genome Sciences and Technology at the University of TN, Knoxville (UTK).

Dr. Culiat’s translational research on the NELL1 gene/pathway was been recognized with awards such as the Oak Ridge YWCA Woman of Distinction in Health, Science and Technology (2008), Biosciences Division Individual Achievement and Significant Event Award (2008), Federal Lab Consortium Excellence in Technology Transfer (Honorable Mention, 2008), Technology Transfer Key Contributor Award (2006) and, from the ORNL-DOE Office of Science, the Outstanding Mentor Award (2006).

Tracy Warren

Chief Executive Officer

Tracy Warren is a general partner of Battelle Ventures and its affiliate fund, Innovation Valley Partners, for which she focuses on investments in health & life sciences with an emphasis on institutional-based transactions.

Ms. Warren has worked closely with the technology transfer and economic development organizations in medical centers, universities and laboratories, including six of the U.S. Department of Energy National Laboratories, and the Health and Life Sciences division of Battelle Memorial Institute, the world’s largest nonprofit research and development organization.

Alongside Dr. Cymbeline Culiat, Ms. Warren co-founded NellOne Therapeutics, a soft-tissue regenerative medicine company based on the NELL1 gene and Dr. Culiat’s work at Oak Ridge National Laboratory. As CEO, she leads the company’s efforts with respect to strategy, fundraising, business development and licensing.

She also co-founded other life sciences companies, such as UPenn spin-out Endovalve (cardiovascular devices), which merged with Micro Interventional Devices, on whose board Ms. Warren sits. And she has led investments in others, such as NuPathe (CNS specialty pharmaceutical), which completed its IPO in 2010 and announced it would be aquired by Endo Specialty in late 2013, and BioNano Genomics (genetic analysis), of which she is board chairman.

In addition to her investment activities, she also provides early-stage leadership to other life sciences businesses, currently serving as an adviser to PDX Pharmaceuticals, LLC, and is a mentor to female entrepreneurs at such innovative companies as TalkSession, TrueMotion Spine, and Life Cycle Laboratories, through her position in the Life Sciences Council of Springboard Enterprises.

Ms. Warren is also applying her expertise in technology transfer and intellectual property as a member of the South Carolina-based Clemson University Research Foundation (CURF) Board of Dirctors. CURF is a non-profit organization dedicated to moving technology from the Clemson University laboratories into commercial markets.

Ms. Warren started in venture capital more than a decade ago, after being an associate in SG Cowen (now Cowen and Company) Securities & Health Care Mergers and Acquisitions and Corporate Finance divisions. She holds a B.S. degree from New York University Stern School of Business and an M.B.A from Columbia Business School, and is a member of the National Association of Corporate Directors.